4-[8-amino-3-[(2S)-1-ethenylsulfonylpiperidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(4-methylpyridin-2-yl)benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[8-amino-3-[(2S)-1-ethenylsulfonylpiperidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(4-methylpyridin-2-yl)benzamide
• 化学式: C₂₆H₂₇N₇O₃S
• 分子量: 517.6
• InChiKey: AETWJPFKOQTCJY-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
  申请人：Merck Sharp & Dohme B.V.

  公开号：US20160159810A1

  公开（公告）日：2016-06-09

  The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

  本发明涉及公式(I)所示的6-5成员融合吡啶环化合物，或其药学上可接受的盐，以及包含这些化合物的制药组合物及其在治疗中的用途。特别地，本发明涉及使用公式(I)所示的6-5成员融合吡啶环化合物治疗布鲁顿酪氨酸激酶（Btk）介导的疾病。
• 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
  申请人：Merck Sharp & Dohme B.V.

  公开号：US20180179212A1

  公开（公告）日：2018-06-28

  The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
• US9290504B2
  申请人：——

  公开号：US9290504B2

  公开（公告）日：2016-03-22
• US9758524B2
  申请人：——

  公开号：US9758524B2

  公开（公告）日：2017-09-12
• US9790226B2
  申请人：——

  公开号：US9790226B2

  公开（公告）日：2017-10-17